Company Overview - Chemed Corporation operates in two segments: VITAS, providing hospice and palliative care, and Roto-Rooter, offering plumbing and related services[11]. - The Company had a total of 15,811 employees as of December 31, 2025, including subsidiaries Roto-Rooter and VITAS[107]. - Roto-Rooter operates 356 leased and owned office and service facilities across 34 states, while VITAS has 182 facilities and 28 inpatient units in 17 states and the District of Columbia[188]. Revenue Sources - Over 90% of VITAS' revenue comes from the Medicare program, indicating a significant reliance on government funding[21]. - Over 95% of VITAS' revenue comes from Medicare and Medicaid payments, primarily on a "per diem" basis, making cost management critical for profitability[53]. - Medicaid reimbursements accounted for approximately 3% of VITAS' revenues in 2025, with state Medicaid programs required to pay at least the same rates as Medicare[69]. - The routine home care rate is tiered, with a higher rate for the first 60 days of care and a lower rate thereafter, plus a Service Intensity Add-on for direct home care visits[58]. - VITAS faces potential reductions in Medicare and Medicaid payments, which could materially decline its net patient service revenue and profits[132]. Regulatory Compliance - VITAS must comply with extensive federal and state regulations to maintain its hospice operations, including conditions of participation for Medicare[32]. - The company maintains an internal regulatory compliance review program to ensure adherence to health regulatory laws[101]. - VITAS' hospices must comply with state licensure requirements, and non-compliance could adversely affect operations and participation in Medicare and Medicaid programs[52]. - Federal and state laws regulate various aspects of the hospice industry, impacting VITAS' operations significantly[100]. - The company cannot assure that its practices will be found compliant with applicable health regulatory laws upon review, which could adversely affect its reputation[101]. Competition and Market Position - The hospice care industry is highly competitive, with VITAS being one of the largest providers in a fragmented market where approximately 20% of providers are not-for-profit[25]. - Roto-Rooter faces competition from local and regional firms, with private equity investments increasing in the home service sector[23]. - Roto-Rooter faces intense competition from numerous fragmented competitors, impacting its ability to maintain or increase customer calls and jobs[123][126]. - VITAS' growth is heavily reliant on maintaining relationships with referral sources, and any loss could adversely affect its profitability[135]. - Competition in the hospice industry is intense, and increased competition could limit VITAS' market position and profitability[145]. Financial Performance and Strategy - The company has engaged in twelve significant acquisitions or divestitures since its inception, focusing on maximizing shareholder value[10]. - The company does not expect material investment in new products or services, focusing instead on improving existing offerings[15]. - The company has significant debt obligations and restrictions on its borrowing capacity, which could adversely affect operational flexibility and financial condition[162]. - Future dividends are contingent upon the Company's earnings, financial condition, and compliance with debt covenants[195]. Risks and Liabilities - Liability claims pose a risk to VITAS, and inadequate insurance coverage could have a material adverse effect on its financial condition[149]. - The company is exposed to natural disasters, particularly hurricanes in Florida, which could impede operations and billing for services[161]. - The company faces risks associated with potential litigation, which could result in substantial damages and affect business operations[168]. - Tariffs on products essential to operations could increase costs and adversely affect margins, particularly for VITAS and Roto-Rooter services[174]. Cybersecurity - A cybersecurity attack in October 2025 allowed unauthorized access to a significant amount of Protected Health Information (PHI), but the threat actor was unable to insert malicious tools into the system[153]. - The company has strengthened its cybersecurity measures following the attack and maintains commercial insurance related to cyberattacks, with costs above a $500,000 deductible covered by insurance[183]. - The company is regularly targeted by cyber threats and must continuously monitor and develop its IT infrastructure to mitigate risks associated with unauthorized access and misuse[157]. - The Audit Committee receives regular reports on cybersecurity issues, which include discussions on risk management processes[185]. Employee and Workforce Management - VITAS paid over $39.2 million in bonuses through the "Difference Maker Program" to retain healthcare workers during the pandemic[116]. - The Company emphasizes the importance of a diverse and inclusive workforce to foster innovation and better serve its diverse customer base[117]. - VITAS is experiencing a nationwide shortage of qualified nurses and aides, which could adversely affect its ability to provide quality services[144]. Environmental and Safety Compliance - The company is currently in compliance with environmental laws and regulations, with capital expenditures for compliance during 2024 and 2025 not material[104]. - The company is subject to environmental and safety compliance costs that could increase expenses and liabilities, potentially impacting financial performance[165]. - The California Air Resources Board is expected to release draft regulations in Q1 2026 regarding climate-related financial risk reports[105]. Future Outlook - Future adjustments to Medicare and Medicaid payment rates may adversely impact VITAS' net patient service revenue and profitability[72]. - The Company acknowledges the potential impact of future public health concerns, similar to the COVID-19 pandemic, which could disrupt operations and service delivery[172]. - Managed care organizations are consolidating, which may exert pressure on VITAS to reduce costs, potentially impacting its financial condition[147].
Chemed(CHE) - 2025 Q4 - Annual Report